Loading...
•
Jun 30, 2021
Tandem Diabetes Q2 2021 Earnings Report
Tandem Diabetes Care's Q2 2021 financial results were announced, featuring increased sales and pump shipments.
Key Takeaways
Tandem Diabetes Care reported a strong second quarter with a 58% increase in sales to $172.1 million and an 81% increase in worldwide pump shipments. The company updated its full-year sales guidance to $670 million to $685 million.
Worldwide pump shipments increased 81% to 33,817 pumps.
Sales increased 58% to $172.1 million.
Gross margin improved to 54% of sales.
Operating margin improved to 3% of sales.
Tandem Diabetes
Tandem Diabetes
Tandem Diabetes Revenue by Geographic Location
Revenue by Geographic Location
United States Revenue
CapyFin.comOutside the United States Revenue
CapyFin.com Forward Guidance
The company updated its financial guidance for the year ending December 31, 2021.
Positive Outlook
- Sales are estimated to be in the range of $670 million to $685 million, representing 34% to 37% annual sales growth compared to 2020.
- International sales are projected to be approximately $160 million to $165 million, indicating 92% to 98% annual sales growth compared to 2020.
- Gross margin is estimated to be approximately 55%.
- Adjusted EBITDA is estimated to be approximately 15% of sales.
Revenue & Expenses
Visualization of income flow from segment revenue to net income